Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
/in Dendritic Cells, International Publications /von 2021-06-28 / Front Cell Dev Biol 2021;9:686544Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
/in International Publications, Newcastle Disease Virus /von 2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
/in International Publications, Newcastle Disease Virus /von 2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial Carcinoma /von 2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors.
/in Dendritic Cells, International Publications /von 2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2021-06-04 / Cancers (Basel) 2021 Jun;13(11)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution